- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07604272
Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males (RIGHT)
Reversing InGuinal Hernia Trial (RIGHT Trial): The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males
This is a prospective, single-center, two-arm Phase 1 safety and feasibility trial evaluating anti-estrogen therapy in men age 50 years and older with symptomatic unilateral inguinal hernias. Participants will be randomized to receive Fulvestrant 250 mg intramuscularly or anastrozole 1 mg orally for 6 months. The study will evaluate safety, tolerability, feasibility, hormone changes, hernia size, patient-reported outcomes, bone density, and imaging-based hernia classification.
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Reclutamento
- Northwestern Memorial Hospital
-
Contatto:
- Nancy Ly, MD
- Numero di telefono: 2624551560
- Email: nancy.ly@nm.org
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male sex
- Age ≥ 50 years at time of enrollment
- Symptomatic unilateral inguinal hernia confirmed on physical examination
- Hernia visible / confirmed on groin ultrasound
- Non-recurrent inguinal hernia (primary hernia only)
- Willing and able to provide written informed consent
- Able and willing to comply with all protocol-required visits, laboratory assessments, imaging, and follow-up
- Willing to use contraception and avoid fathering a child during study participation and for 12 months after last dose
- Willing to be counseled regarding vitamin D and calcium supplementation
Exclusion Criteria:
Hernia Characteristics
- Scrotal hernia (any)
- Bilateral inguinal hernia
- Recurrent inguinal hernia (prior repair at same site)
Renal & Hepatic
- Clinically significant renal dysfunction judged by investigator to increase study risk
- Clinically significant hepatic dysfunction at baseline
Hematologic
■ Clinically significant baseline hematologic abnormality (including elevated hematocrit or polycythemia)
Urologic / Prostate
- Symptomatic benign prostatic hyperplasia (BPH) requiring active medical or procedural treatment
- Clinically significant untreated prostate disease
Skeletal / Bone
- Baseline osteoporosis (T-score ≤ -2.5 on DEXA at any site)
- Recent fragility fracture (within prior 12 months or as judged by investigator)
- Other clinically significant skeletal vulnerability judged to increase risk from estrogen suppression
Immunosuppression ■ Active immunosuppression (e.g., systemic corticosteroids, biologic agents, post-transplant regimens)
Psychiatric
■ Unstable or uncontrolled psychiatric illness that, in the investigator's judgment, would interfere with safe study participation
Reproductive / Fertility ■ Actively pursuing fertility or planning conception during study participation
Prior / Concomitant Therapy
- Current use of androgen replacement therapy, exogenous estrogen, or other endocrine-active agents that would confound study interpretation
- Prior or current use of aromatase inhibitor or selective estrogen receptor modulator / degrader within 6 months of enrollment
- Active malignancy under treatment
General
■ Any other clinically significant medical condition, laboratory abnormality, or circumstance that, in the investigator's judgment, would place the participant at unacceptable risk or compromise study integrity
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Anastrozole 1 mg
Participants will receive anastrozole 1 mg orally once daily for 6 months. |
Participants will receive anastrozole 1 mg orally once daily for 6 months. |
|
Sperimentale: Fulvestrant 250 mg
Participants will receive fulvestrant 250 mg intramuscularly monthly for 6 doses, given at the baseline visit and at Months 1 through 5. |
Participants will receive fulvestrant 250 mg intramuscularly on Days 1 and 29, then monthly for 6 months. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Composite Safety Event Rate
Lasso di tempo: 6 months
|
Proportion of participants experiencing a composite safety event, defined as hernia-related complications including incarceration, strangulation, or emergent surgery; drug-related toxicity Grade 2 or higher by CTCAE v5.0; or procedure/treatment-related events Clavien-Dindo Grade III or higher. |
6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Serum Estradiol Level
Lasso di tempo: Baseline to 6 months
|
Change in Serum Estradiol Level |
Baseline to 6 months
|
|
Serum Testosterone Level
Lasso di tempo: Baseline to 6 months
|
Change in Serum Testosterone Level |
Baseline to 6 months
|
|
Serum LH Level
Lasso di tempo: Baseline to 6 months
|
Change in Serum LH Level |
Baseline to 6 months
|
|
Serum FSH Level
Lasso di tempo: Baseline to 6 months
|
Change in Serum FSH Level |
Baseline to 6 months
|
|
Hernia Size on Ultrasound
Lasso di tempo: Baseline to 6 months; baseline to 1 year
|
Change in Hernia Size on Ultrasound |
Baseline to 6 months; baseline to 1 year
|
|
European Registry for Abdominal Wall Hernias Quality of Life (EuraHS-QoL) Score
Lasso di tempo: Baseline to 6 months; baseline to 1 year
|
The EuraHS-QoL questionnaire assesses pain, activity restriction, and cosmetic discomfort related to abdominal wall hernias. Scores range from 0 to 90, with higher scores indicating worse hernia-related quality of life and symptom burden. |
Baseline to 6 months; baseline to 1 year
|
|
Euro Quality of Life 5 Dimension 5 Level (EQ-5D-5L) Score
Lasso di tempo: Baseline to 6 months; baseline to 1 year
|
EQ-5D-5L index value, where 1 indicates full health and 0 indicates a state equivalent to death; values below 0 are possible. Higher scores indicate better health-related quality of life. EQ VAS self-rated health is scored from 0 (worst) to 100 (best imaginable health). |
Baseline to 6 months; baseline to 1 year
|
|
Bone Mineral Density on DEXA
Lasso di tempo: Baseline, 3 months, and 1 year
|
Change in Bone Mineral Density on DEXA |
Baseline, 3 months, and 1 year
|
|
Hernia Type on CT
Lasso di tempo: Baseline
|
Characterization of the inguinal hernia on non-contrast CT of the pelvis. |
Baseline
|
|
AUA International Prostate Symptom Score (IPSS)
Lasso di tempo: Baseline to 1 year
|
Seven-item questionnaire of urinary symptoms. Total score ranges from 0 to 35; higher scores indicate more severe symptoms. |
Baseline to 1 year
|
|
PROMIS Sexual Function and Satisfaction
Lasso di tempo: Baseline to 1 year
|
PROMIS Sexual Function and Satisfaction domain scores, reported as T-scores (mean 50, SD 10 in the U.S. reference population). |
Baseline to 1 year
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- HerniaSurge Group. International guidelines for groin hernia management. Hernia. 2018 Feb;22(1):1-165. doi: 10.1007/s10029-017-1668-x. Epub 2018 Jan 12.
- Potluri T, You T, Yin P, Coon J 5th, Stulberg JJ, Dai Y, Escobar DJ, Lieber RL, Zhao H, Bulun SE. Estrogen receptor-alpha ablation reverses muscle fibrosis and inguinal hernias. J Clin Invest. 2025 Feb 4;135(6):e179137. doi: 10.1172/JCI179137.
- Zhao H, Zhou L, Li L, Coon V J, Chatterton RT, Brooks DC, Jiang E, Liu L, Xu X, Dong Z, DeMayo FJ, Stulberg JJ, Tourtellotte WG, Bulun SE. Shift from androgen to estrogen action causes abdominal muscle fibrosis, atrophy, and inguinal hernia in a transgenic male mouse model. Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):E10427-E10436. doi: 10.1073/pnas.1807765115. Epub 2018 Oct 16.
- Matthews RD, Neumayer L. Inguinal hernia in the 21st century: an evidence-based review. Curr Probl Surg. 2008 Apr;45(4):261-312. doi: 10.1067/j.cpsurg.2008.01.002. No abstract available.
- Potluri T, Taylor MJ, Stulberg JJ, Lieber RL, Zhao H, Bulun SE. An estrogen-sensitive fibroblast population drives abdominal muscle fibrosis in an inguinal hernia mouse model. JCI Insight. 2022 Apr 19;7(9):e152011. doi: 10.1172/jci.insight.152011.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Condizioni patologiche, anatomiche
- Necrosi
- Ernia, Addominale
- Condizioni patologiche, segni e sintomi
- Fibrosi
- Ernia
- Ernia, inguinale
- Cancrena
- Ormoni
- Ormoni, sostituti ormonali e antagonisti ormonali
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Azoli
- Composti policiclici
- Steroidi
- Composti anelli fusi
- Nitrili
- Estradiolo
- Estrene
- Estrane
- Congeneri di estradiolo
- Ormoni steroidi gonadali
- Ormoni gonadali
- Triazoli
- Fulvestrant
- Anastrozolo
Altri numeri di identificazione dello studio
- 00225501
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Individual participant data will not be shared outside the study team. Aggregate study results may be disseminated through presentations and publications.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .